Covishield

File Image : BHU study said that nearly 30% of Covaxin takers had health issues during one-year follow up.

ICMR Distances Itself From BHU's 'Poorly Designed' Study On Covaxin Side Effects

BY Asmita Ravi Shankar

AP : AstraZeneca's Covid-19 Vaccine |

AstraZeneca's Covid-19 Vaccine Can Cause A Second 'Rare' Blood Clotting Disorder? | What Research Says

BY Jheelum Basu

AP : AstraZeneca Covid-19 Vaccine |

AstraZeneca Rolls Back Covid-19 Vaccine Amid Row Over Side- Effects, Terms It 'Purely Coincidental'

BY Outlook Web Desk

Getty's Images

Covishield Scrutiny: Rare But Severe Side Effects Spark Controversy

BY Outlook Web Desk

PTI : Bharat Biotech's Covid-19 shot 'Covaxin' |

Bharat Biotech Highlights Covaxin's 'Safety First' Feature Amid AstraZeneca's Covishield Row Over Side Effects

BY Outlook Web Desk

X/@BhavikaKapoor5 : Some users on the microblogging platform X (formerly Twitter) noticed the change in CoWIN certificates.

PM Modi's Pic Disappears From CoWIN Certificates Amid Covishield Side Effects Row; Health Ministry Responds

BY Outlook Web Desk

File image : Covishield, developed by AstraZeneca and Oxford University during the pandemic, was produced by the Serum Institute (SII) in India

'Sympathy To Those Who Lost Loved Ones': AstraZeneca On Covishield Side Effects

BY Outlook Web Desk

Advertisement

Political Row over side effects of Covishield vaccine

'Who Would Be Responsible For Heart Attack Deaths': Oppn Parties Slam BJP Over Covishield Row

BY PTI

File image : Covishield, developed by AstraZeneca and Oxford University during the pandemic, was produced by the Serum Institute of India

Covishield Maker AstraZeneca Admits Its Covid Vaccine Can Cause Rare Side Effects

BY Outlook Web Desk

Only Covaxin To Be Administered To Children, Registrations On CoWIN From January 1, Health Ministry

Serum Institute Seeks Inclusion Of Covovax On CoWIN As Heterologous Booster Dose For Adults

BY PTI

Covid-19 vaccine booster shots

Covishield Administered In India ‘Worse’ Due To Adverse Health Impact: Expert

BY PTI

Covid-19 vaccine for kids aged 5-12 years.(Representational image)

Covovax Booster Dose For Covid-19, Its Efficacy Rate And How Does It Work? All You Need To Know

BY Outlook Web Desk

Covid-19 vaccine for kids aged 5-12 years.(Representational image)

SII's Free Supply Of Covishield To Centre: First Lot Of 80 Lakh Doses Set For Dispatch

BY PTI

Corbevax and Covovax vaccines against Covid-19 cleared by Centre.(File photo-Representational image)

Corbevax As Booster Maximises Protection In Covishield Vaccinated People: AIG Hospitals Study

BY PTI

Advertisement

Centre said it's not liable for Covid-19 vaccine-related deaths

Government Not Liable For Vaccine-Related Deaths: Centre To Supreme Court

BY Outlook Web Desk

Telangana Asks Centre To Supply 50 Lakh Doses Of Covishield To Ramp Up Booster Jabs

Telangana Asks Centre To Supply 50 Lakh Doses Of Covishield To Ramp Up Booster Jabs

BY Outlook Web Desk

Immunity From Natural Covid Infection, Vaccines Not Absolute: Minister of State for Health

Immunity From Natural Covid Infection, Vaccines Not Absolute: Minister of State for Health

BY Outlook Web Desk

Health Ministry Seeks 5 Cr Free Covishield Doses From GAVI Under COVAX

Health Ministry Seeks 5 Cr Free Covishield Doses From GAVI Under COVAX

BY Outlook Web Desk

Biological E Seeks EUA For Corbevax As Booster In Adults Vaccinated With Covishield, Covaxin

Biological E Seeks EUA For Corbevax As Booster In Adults Vaccinated With Covishield, Covaxin

BY Outlook Web Desk

Covishield and Covaxin.

SII To Give Free Covishield Vials To Pvt Vaccination Centres To Compensate For Price Difference

BY Outlook Web Desk

Second dose of COVID-19 vaccination. (Representational image)

Second Covishield Dose Can Be Given Between 8-16 Weeks After First Dose, Says NTAGI Reducing Gap

BY Outlook Web Desk

Advertisement

COVID-19 test, covid, covid-19, testing, vaccination, india

Ladakh Records 24 New COVID-19 Cases

BY Outlook Web Desk

Covishield And Covaxin Get Regular Market Approval For Use In Adult Population

Covishield And Covaxin Get Regular Market Approval For Use In Adult Population

BY Outlook Web Desk

Representational Image

DCGI Grants Regular Market Approval For Covishield, Covaxin

BY PTI

Representational Image

Regular Market Approval Likely To Cap Covishield, Covaxin Price At Rs 275

BY Outlook Web Desk

load more stories

<style id="xhwtk"><delect id="xhwtk"></delect></style>